Add to ORKGAIM: To determine the impact of postoperative chemoradiation (POCR) on overall survival (OS) after resection of pancreatic adenocarcinoma (PAC) in elderly (≥75 years) patients. MATERIALS AND METHODS: A multi-center retrospective review of 1248 patients who underwent complete resection with macroscopically negative margins (R0-1) for invasive PAC was performed. Exclusion criteria included age <75 years, metastatic or unresectable disease at surgery, macroscopic residual disease (R2), treatment with intraoperative radiotherapy (IORT) and postoperative death. RESULTS: A total of 98 patients were included in the analysis (males=39.8%, females=60.2%; R1 resections=33.7%; pN1=61.2%); 63 patients received POCR and 26 patients received a...
Background: The treatment options for patients with locally advanced pancreatic cancer (LAPC) have i...
BackgroundDue to underrepresentation in randomized controlled trials among old people (≥65 years old...
Background: Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulti...
AIM: To determine the impact of postoperative chemoradiation (POCR) on overall survival (OS) afte...
Background: We sought to determine the effects of post-operative radiation therapy (PORT) and lymph ...
BACKGROUND: The number of elderly patients with pancreatic cancer is growing, however clinical data ...
Background: The number of elderly patients with pancreatic cancer is growing, however clinical data ...
Background: Adjuvant chemotherapy improves survival for patients with resected pancreatic cancer. El...
none16siPurpose: To determine the impact of chemoradiation therapy (CRT) on overall survival (OS) af...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth or fifth leading cause of death from cancer in...
Background: At a national level, it is unknown to what degree elderly patients with pancreatic or pe...
Background: At a national level, it is unknown to what degree elderly patients with pancreatic or pe...
BackgroundDue to underrepresentation in randomized controlled trials among old people (≥65 years old...
BACKGROUND: In treating pancreatic ductal adenocarcinoma (PDAC), age does not represent a contraind...
Background: The treatment options for patients with locally advanced pancreatic cancer (LAPC) have i...
BackgroundDue to underrepresentation in randomized controlled trials among old people (≥65 years old...
Background: Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulti...
AIM: To determine the impact of postoperative chemoradiation (POCR) on overall survival (OS) afte...
Background: We sought to determine the effects of post-operative radiation therapy (PORT) and lymph ...
BACKGROUND: The number of elderly patients with pancreatic cancer is growing, however clinical data ...
Background: The number of elderly patients with pancreatic cancer is growing, however clinical data ...
Background: Adjuvant chemotherapy improves survival for patients with resected pancreatic cancer. El...
none16siPurpose: To determine the impact of chemoradiation therapy (CRT) on overall survival (OS) af...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth or fifth leading cause of death from cancer in...
Background: At a national level, it is unknown to what degree elderly patients with pancreatic or pe...
Background: At a national level, it is unknown to what degree elderly patients with pancreatic or pe...
BackgroundDue to underrepresentation in randomized controlled trials among old people (≥65 years old...
BACKGROUND: In treating pancreatic ductal adenocarcinoma (PDAC), age does not represent a contraind...
Background: The treatment options for patients with locally advanced pancreatic cancer (LAPC) have i...
BackgroundDue to underrepresentation in randomized controlled trials among old people (≥65 years old...
Background: Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulti...